CARsgen Therapeutics (HKG:2171) expects its H1 loss to narrow year over year, according to a Hong Kong bourse filing Friday.
The cell therapies producer said it expects a loss of up to 80 million yuan for the six months ended June 30, as compared with a loss of 351 million yuan in the year-ago period.
CARsgen expects to report its financial results by the end of August.
Shares of the company were up over 1% in morning trade Friday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.